Cresset Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cresset Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,138	Closed	-$517K	–	1112
2021 Q4	$517K	Buy	+6,138	New	+$499K	0.01%	687
2019 Q2	–	Sell	-6	Closed	–	–	1397
2019 Q1	$0	Sell	6 -16	-73%	-$914	﹤0.01%	2086
2018 Q4	$1K	Buy	+22	New	+$1.2K	﹤0.01%	1568

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cresset Asset Management's RARE Position: Q1 2022 in Review

Cresset Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2022, closing a stake of 6,138 shares — an estimated $517K sold.

Cresset Asset Management first reported a position in RARE in Q4 2018 and held it in 3 quarters. The position peaked at $517K in Q4 2021. 239 funds tracked by Wall St. Rank hold RARE as of Q1 2022.

Cresset Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2022 after selling out during the quarter.
Cresset Asset Management sold 6,138 Ultragenyx Pharmaceutical shares in Q1 2022, an estimated $517K.
Cresset Asset Management first reported a position in Ultragenyx Pharmaceutical in Q4 2018 and held it in 3 quarters.
Cresset Asset Management's Ultragenyx Pharmaceutical position peaked at $517K in Q4 2021.
239 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2022.

Based on Cresset Asset Management's 13F filing for Q1 2022, filed 16 May 2022.